News|Articles|January 4, 2022

In the Lab eNewsletter

  • Pharmaceutical Technology's In the Lab eNewsletter, January 2022
  • Volume 17
  • Issue 1

OpenEye Scientific and Specifica Partner to Launch Orion Antibody Discovery Suite

The partnership between OpenEye Scientific and Specifica has generated AbXtract, an antibody discovery model that is included in the Orion Antibody Suite.

OpenEye Scientific and Specifa have jointly developed a software offering known as the OpenEye Orion Antibody Discovery Suite. The first offering from the suite will be AbXtract, an antibody discovery module developed by Specifica.

The Orion Antibody Suite has been described as the only cloud-native. fully integrated software-as-a-service molecular modeling platform, according to a Dec. 2, 2021, press release. The software suite is intended to combine the storage and computational scalability of Amazon Web Services with powerful tools for data sharing, visualization, and analysis in an open development platform.

AbXtract uses proprietary artificial intelligence methods to analyze large amounts of sequence data. The model is designed to help antibody engineers and bioinformaticians uncover diverse antibody sets with ideal properties for downstream therapeutics development.

“What AbXtract does is democratize the use of next-generation sequencing in antibody discovery, letting Orion take care of storage and analysis,” said Andrew Bradbury, co-founder and chief scientific officer of Specifica, in the press release. “Antibody discovery projects that were previously out of reach because of software, hardware, computation, or data sharing limitations have now become possible with AbXtract on Orion.”

Source: Specifica


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.